Eczema has a latitude gradient that is hard to ignore. Flares are more common and more severe in winter, in northern countries, and in people who spend most of the day indoors. Vitamin D is the most obvious explanation, since cutaneous synthesis depends on ultraviolet B reaching the skin at a sufficient angle, and that angle is unavailable for several months a year above certain latitudes.
The seasonal pattern is real but not simple
Ultraviolet B at wavelengths around 290 to 315 nanometres converts 7-dehydrocholesterol in the epidermis into a previtamin D3 that isomerises to vitamin D3. The reaction requires the sun to be high enough in the sky, which at northern latitudes means it stops in late autumn and resumes in early spring. In northern Europe, parts of Canada and the northern United States, the cutaneous route is effectively closed for four to five months.
Eczema flares follow a similar calendar, but so does dry indoor air, hot showers, wool clothing and the viral infections that trigger flares in children. Separating the vitamin D effect from the winter effect is difficult, and studies that measure both tend to find correlations of modest size rather than a dominant cause.
The pattern is still worth acting on, because the intervention is cheap and the downside is small. It is the interpretation that needs care: a seasonal flare does not prove a deficiency, and a supplement does not replace topical treatment.
What vitamin D does in the skin
Keratinocytes express the enzyme that converts vitamin D to its active form, and they carry the receptor that responds to it. In the epidermis, the active form promotes differentiation of keratinocytes and supports the production of antimicrobial peptides such as cathelicidin, which are part of the innate defence against Staphylococcus aureus.
That last point matters because S aureus colonisation is a major driver of eczema severity. Vitamin D also influences T cell responses, shifting the balance away from the Th2-dominated inflammation that characterises atopic dermatitis, at least in laboratory models.
The barrier connection runs through filaggrin and the lipid matrix. Vitamin D signalling affects the expression of proteins involved in cornification, and low levels are associated with higher transepidermal water loss in some studies. None of this makes vitamin D a treatment for eczema, but it does explain why deficiency and skin disease travel together.
What the supplementation trials show
The trial literature is mixed in a way that is informative. Studies in people with documented deficiency tend to show improvement in severity scores. Studies in unselected populations, where most participants already have adequate levels, tend to show little or nothing. This is the classic pattern for a nutrient that is being used to correct a deficit rather than to treat a disease.
Dose matters as much as baseline. Daily low-dose supplementation appears more consistent than large intermittent bolus doses, which is true for several outcomes beyond skin. The trials that used very high single doses have generally been the ones with null or adverse results.
The practical reading is that testing is more useful than guessing. A blood level tells you if you are correcting a deficiency or adding a supplement to a replete system, and those are different clinical situations with different expected benefits.
Safety boundaries and the upper limit
Vitamin D is fat soluble and accumulates. The tolerable upper intake for adults is generally cited around 4000 international units per day for supplementation without medical supervision, and toxicity produces hypercalcaemia with nausea, weakness, confusion and kidney stones. It is uncommon at standard doses and entirely avoidable.
Some situations need clinician involvement rather than a bottle: kidney disease, granulomatous conditions such as sarcoidosis, and any use of thiazide diuretics, all of which change the handling of calcium. Infants and pregnant women have their own dosing ranges, and self-dosing in pregnancy is not advisable.
Sun exposure is not a reliable dosing strategy. There is no dose-response that can be measured, the amount synthesised depends on skin type, age, latitude and surface area exposed, and the ultraviolet exposure that produces it also produces DNA damage. Ten to fifteen minutes of midday sun on the arms in summer is a reasonable habit; deliberately burning to make vitamin D is not.
What this does not replace
Topical corticosteroids, calcineurin inhibitors, moisturizers with the right lipid ratio and avoidance of triggers remain the treatment for atopic dermatitis. Vitamin D is an adjunct, and framing it as a natural alternative to steroids is the most common way this information gets misused. Uncontrolled eczema leads to sleep loss, infection and skin thickening, and none of those are improved by a supplement alone.
The same caution applies to the marketing of vitamin D for acne, psoriasis and wound healing, where the evidence is weaker than for eczema and the mechanism is more speculative.
When this approach is not appropriate
Eczema that is weeping, crusted, painful or spreading may be infected and needs antibiotics rather than a supplement. Widespread flares in an infant, or any flare with fever, should be seen promptly. If eczema is severe enough to disturb sleep most nights, the priority is a dermatology appointment, not a vitamin level.
This is general information, not medical advice. Anyone taking a supplement should tell their clinician, because the interaction with diuretics, cardiac medication and kidney disease is not trivial, and the correct dose for a person with a deficiency is a clinical decision rather than a label instruction.